CP
AZN icon

Castleview Partners’s AstraZeneca AZN Stock Holding History

Castleview Partners’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-31
Closed -$4.83K – 572
2024
Q2 		$4.83K Buy
31
+13
+72% +$1.96K ﹤0.01% 627
2024
Q1 		$2.44K Sell
18
-134
-88% -$17.7K ﹤0.01% 723
2023
Q4 		$20.4K Hold
152
– – 0.01% 435
2023
Q3 		$20.5K Hold
152
– – 0.02% 358
2023
Q2 		$21.7K Sell
152
-6
-4% -$883 0.02% 347
2023
Q1 		$21.7K Buy
+158
New +$21.3K 0.02% 337
2022
Q4 		– Sell
-157
Closed -$17K – 655
2022
Q3 		$17K Sell
157
-1,643
-91% -$208K 0.02% 333
2022
Q2 		$11K Buy
1,800
+1,513
+527% +$199K 0.01% 447
2022
Q1 		$38K Buy
+287
New +$34.4K 0.02% 376
2021
Q2 		$3K Buy
+28
New +$3.07K ﹤0.01% 823

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Castleview Partners's AZN Position: Q3 2024 in Review

Castleview Partners sold out of AstraZeneca (AZN) in Q3 2024, closing a stake of 31 shares — an estimated $4.83K sold.

Castleview Partners first reported a position in AZN in Q2 2021 and held it in 10 quarters. The position peaked at $38K in Q1 2022. 1,230 funds tracked by Wall St. Rank hold AZN as of Q3 2024.

  • Castleview Partners reported no remaining AstraZeneca position as of Q3 2024 after selling out during the quarter.
  • Castleview Partners sold 31 AstraZeneca shares in Q3 2024, an estimated $4.83K.
  • Castleview Partners first reported a position in AstraZeneca in Q2 2021 and held it in 10 quarters.
  • Castleview Partners's AstraZeneca position peaked at $38K in Q1 2022.
  • 1,230 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2024.

Based on Castleview Partners's 13F filing for Q3 2024, filed 9 Oct 2024.